Alpha5GABAA receptor activity sets the threshold for long-term potentiation and constrains hippocampus-dependent memory.
Synaptic plasticity, which is the neuronal substrate for many forms of hippocampus-dependent learning, is attenuated by GABA type A receptor (GABA(A)R)-mediated inhibition. The prevailing notion is that a synaptic or phasic form of GABAergic inhibition regulates synaptic plasticity; however, little is known about the role of GABA(A)R subtypes that generate a tonic or persistent inhibitory conductance. We studied the regulation of synaptic plasticity by alpha5 subunit-containing GABA(A)Rs (alpha5GABA(A)Rs), which generate a tonic inhibitory conductance in CA1 pyramidal neurons using electrophysiological recordings of field and whole-cell potentials in hippocampal slices from both wild-type and null mutant mice for the alpha5 subunit of the GABA(A)R (Gabra5(-/-) mice). In addition, the strength of fear-associated memory was studied. The results showed that alpha5GABA(A)R activity raises the threshold for induction of long-term potentiation in a highly specific band of stimulation frequencies (10-20 Hz) through mechanisms that are predominantly independent of inhibitory synaptic transmission. The deletion or pharmacological inhibition of alpha5GABA(A)Rs caused no change in baseline membrane potential or input resistance but increased depolarization during 10 Hz stimulation. The encoding of hippocampus-dependent memory was regulated by alpha5GABA(A)Rs but only under specific conditions that generate moderate but not robust forms of fear-associated learning. Thus, under specific conditions, alpha5GABA(A)R activity predominates over synaptic inhibition in modifying the strength of both synaptic plasticity in vitro and certain forms of memory in vivo.
Martin
Loren J
LJ
Department of Physiology, Institute of Medical Science, University of Toronto, Toronto, Ontario M5S 1A8, Canada. ljmartin@bu.edu
Zurek
Agnieszka A
AA
MacDonald
John F
JF
Roder
John C
JC
Jackson
Michael F
MF
Orser
Beverley A
BA
D000818:Animals; D001245:Association Learning; D056547:CA1 Region, Hippocampal / Q000187:drug effects / Q000502:physiology; D017097:Electric Impedance; D004558:Electric Stimulation / Q000379:methods; D005239:Fear; D058787:GABA-A Receptor Antagonists; D006624:Hippocampus / Q000187:drug effects / Q000502:physiology*; D066298:In Vitro Techniques; D017774:Long-Term Potentiation / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D008568:Memory / Q000187:drug effects / Q000502:physiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009433:Neural Inhibition / Q000187:drug effects / Q000502:physiology; D018408:Patch-Clamp Techniques; D017966:Pyramidal Cells / Q000187:drug effects / Q000502:physiology; D011963:Receptors, GABA-A / Q000235:genetics / Q000378:metabolism*; D017470:Receptors, Glutamate / Q000378:metabolism; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology
D058787:GABA-A Receptor Antagonists; C496250:Gabra5 protein, mouse; D011963:Receptors, GABA-A; D017470:Receptors, Glutamate
PLoS One. 2008 Aug 21;3(8):e3029
18716656
Science. 2006 Aug 25;313(5790):1093-7
16931756
J Neurophysiol. 1999 Jun;81(6):2814-22
10368399
J Neurosci. 2002 Jul 1;22(13):5572-80
12097508
Neuropsychopharmacology. 1999 Apr;20(4):346-56
10088135
Anesthesiology. 2009 Nov;111(5):1025-35
19809285
J Neurophysiol. 2008 Aug;100(2):932-44
18509076
Neuron. 2004 Sep 30;44(1):5-21
15450156
Nature. 1983 Feb 17-23;301(5901):603-4
6298626
Brain Res. 1999 Mar 20;822(1-2):265-70
10082908
Br J Pharmacol. 2002 Aug;136(7):965-74
12145096
Psychopharmacology (Berl). 2009 Jan;202(1-3):207-23
18936916
Cell Tissue Res. 2006 Nov;326(2):439-46
16862427
Physiol Rev. 2007 Oct;87(4):1215-84
17928584
Hippocampus. 1998;8(3):289-98
9662142
Trends Neurosci. 2004 May;27(5):262-9
15111008
J Neurosci. 2009 Dec 2;29(48):15341-50
19955387
Pavlov J Biol Sci. 1980 Oct-Dec;15(4):177-82
7208128
Prog Biophys Mol Biol. 2005 Jan;87(1):33-46
15471589
J Physiol. 2004 Sep 15;559(Pt 3):721-8
15284346
J Neurophysiol. 2000 Nov;84(5):2484-93
11067991
J Neurosci. 2008 Nov 12;28(46):11959-69
19005061
Neuropharmacology. 2002 Sep;43(4):530-49
12367600
Hippocampus. 2005;15(4):418-26
15669102
Eur J Neurosci. 2000 Feb;12(2):425-36
10712623
Curr Opin Neurobiol. 1993 Dec;3(6):917-24
8124075
Drug Metab Dispos. 2006 May;34(5):887-93
16455808
J Neurophysiol. 1992 Jul;68(1):197-212
1381418
Neurosci Lett. 1985 Sep 16;60(1):19-23
2997672
J Neurophysiol. 2001 Jan;85(1):399-406
11152740
Cell. 2004 Nov 24;119(5):719-32
15550252
Mol Pharmacol. 2001 Apr;59(4):814-24
11259626
J Neurophysiol. 2002 May;87(5):2624-8
11976398
J Pharmacol Exp Ther. 2006 Mar;316(3):1335-45
16326923
Psychopharmacology (Berl). 2006 Nov;188(4):619-28
16633803
Neuropharmacology. 2010 Mar;58(3):668-75
19941877
Eur J Neurosci. 1995 Jul 1;7(7):1495-501
7551175
Nature. 1994 May 19;369(6477):233-5
7514272
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3662-7
14993607
Hippocampus. 2005;15(7):827-40
16149082
Neuropharmacology. 1996;35(9-10):1331-5
9014149
J Physiol. 1996 Dec 15;497 ( Pt 3):753-9
9003560
J Neurosci. 2006 Apr 5;26(14):3713-20
16597725
Proc Natl Acad Sci U S A. 1992 May 15;89(10):4363-7
1350090
Brain Res Dev Brain Res. 2005 Jan 1;154(1):15-23
15617751
Neuron. 2000 Apr;26(1):197-205
10798404
J Neurophysiol. 2006 May;95(5):2796-807
16452257
Neuropharmacology. 2006 Nov;51(6):1023-9
17046030
J Neurophysiol. 1987 Jan;57(1):325-40
3559679
J Neurophysiol. 2009 Mar;101(3):1179-91
19073796
J Neurochem. 2006 Jun;97(5):1349-56
16573642
Learn Mem. 2000 May-Jun;7(3):170-9
10837506
Eur J Neurosci. 2002 Jul;16(1):145-8
12153539
J Neurosci. 2005 Oct 26;25(43):10016-24
16251450
Science. 2008 Jul 4;321(5885):53-7
18599766
J Med Chem. 2004 Nov 18;47(24):5829-32
15537339
Mol Pharmacol. 1992 Apr;41(4):683-7
1314944
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12772-7
11675507
Prog Neurobiol. 1998 Feb;54(3):333-48
9481802
Neuroreport. 2002 Dec 3;13(17):2355-8
12488826
Neuron. 2007 Dec 6;56(5):763-70
18054854
Neurobiol Learn Mem. 2008 Feb;89(2):87-94
17638582
J Physiol. 1996 Feb 15;491 ( Pt 1):163-76
9011608
Mol Pharmacol. 1996 Jul;50(1):119-27
8700104
Nature. 2001 Jan 4;409(6816):88-92
11343119
Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8980-5
12084936
Neuron. 2003 May 8;38(3):433-45
12741990
Neuron. 2001 Feb;29(2):485-96
11239437
Mol Pharmacol. 1998 Nov;54(5):928-33
9804628
Neuron. 2000 Mar;25(3):663-72
10774733
J Psychopharmacol. 2002 Dec;16(4):313-9
12503830
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14439-44
14623958
J Neurophysiol. 2007 Oct;98(4):2244-54
17715197
Mol Pharmacol. 2003 Jan;63(1):2-8
12488530
Nat Rev Neurosci. 2005 Mar;6(3):215-29
15738957
J Neurosci. 1999 May 15;19(10):4180-8
10234045
EMBO Rep. 2006 Nov;7(11):1104-10
17077866
J Neurosci. 1999 Dec 15;19(24):10977-84
10594078
Neuropharmacology. 2007 Dec;53(7):810-20
17888460
Nature. 1998 Dec 3;396(6710):433-9
9853749
Eur J Neurosci. 2004 Oct;20(7):1928-36
15380015
Neuropharmacology. 2007 Jan;52(1):60-70
16904707
J Physiol. 1983 Jan;334:33-46
6306230
J Comp Neurol. 2006 Nov 20;499(3):458-70
16998906
J Neurosci. 2008 Feb 6;28(6):1421-6
18256262
Neuroscience. 2000;101(4):815-50
11113332